'No Need For Panic' On Pharma IP Front Post Brexit Vote
This article was originally published in SRA
Pharmaceutical companies worried about how the UK's vote to leave the EU will affect their IP rights are being advised to 'keep calm and carry on' as instruments for securing patent protection in the UK will remain unaffected by the departure.
You may also be interested in...
The withdrawal of the marketing authorization application for Dexamethasone Taw as a treatment for COVID-19 patients was revealed today in the January meeting agenda of the European Medicines Agency’s human medicines committee, the CHMP.
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.
New medicines under evaluation at the European Medicines Agency.